News updates: nano-based vaccines and therapeutics for treatment of COVID-19

A timeline of responses from researchers, biotechnology companies and funding bodies in a global effort to develop, test and distribute vaccines and therapeutics for COVID-19 as quickly and safely as possible.   Novavax’s COVID-19 vaccine candidate meets primary endpoint in interim Phase III study analysis Novavax (MD, USA) has announced that, at interim analysis, the primary endpoint in its Phase III trial of its COVID-19 vaccine candidate, NVX-CoV2373, in the UK has been met, with data indicating a point estimate of vaccine efficacy of 89.3%. To read more on this development, see here >>> Swissmedic grants temporary authorization for Moderna’s...